The following presentations are available to be viewed up to 1 week after the Biotech and Money London conference.
The individuals associated with each presentation will be present and can be contacted to arrange 1-2-1 meetings at the Biotech and Money London congress.
If you are an attending delegate, login to Meeting Mojo using the link below, along with your email address and your password to set up onsite meetings directly:
Lipotype - Innovative Lipidomics Technology for Biomarker Identification and Precision Medicine
Lipotype delivers comprehensive, absolutely quantitative lipid analysis services for clinical and biological samples on a high-throughput scale.
MRC Technology is an independent life science medical research charity committed to drastically improving positive patient outcomes everywhere.
As a champion for human health, MRC Technology partners with academic, biotechnology, pharmaceutical, and charity organisations to move promising medical research forward into viable and accessible patient treatments. (46 words)
Tags: Drug Discovery; Antibodies; Medicinal Chemistry; Collaboration
Andrew Mercieca, Director of Finance, MRCT
MSI Ltd. - Mitochondrial Substrate Invention Ltd.
Dr Larisa Andreeva, Director / Co-inventor, MSI Ltd.
Poiesis Therapeutics - Innovative Healthcare for Pets
Poïesis Therapeutics is a biotechnology start-up focused on sourcing and in-licensing innovative late stage therapeutics, diagnostics and research tools from human biomedical research and then developing them to address unmet needs in the veterinary market for companion animals – horses, dogs and cats.
Jessica Dugan, President and CEO, Poiesis Therapeutics
Pluristem Therapeutics - Placental Cell Therapies - Advancing Cell Therapeutic Products for Clinical Use
Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to develop and manufacture safe and effective cell therapy products. We believe our cutting edge technology can produce therapies that will help people affected by inflammation, ischemia, hematological disorders, and acute radiation syndrome, and establish us as a leading company in the cell therapy arena.
Zami Aberman, President and CEO, Pluristem
Re-Pharm – Using Smart Reprofiling to identify valuable new uses for old molecules
Re-Pharm is a clinical-stage company focussed on the development of new therapeutics through re-profiling of existing, marketed compounds. The company has developed a re-profiling platform; through which we have identified a series of commercially interesting opportunities. Our lead asset RP0217 was identified in this way and has completed pre-clinical development in a variety of topical anti-inflammatory indications. The company is looking to raise a finance round to complete first-in-man studies on RP0217 and to build out the pipeline of other repositioned assets.
Tags – Re-profiling, computational chemistry, anti-inflammatory, ophthalmic, respiratory.
View Audio Assisted Powerpoint Presentation (please enable sound to hear CEO commentary)
SEEK Group - Funding opportunities in influenza and cancer
Post proof of principle assets focused into new investment opportunity and vehicles for next stage growth
SEEK Group, headquartered in London, is involved in research and development, sales of over the counter and prescription medicines and management and operation of clinics. It undertakes all these activities in order to bring safe, effective and low costs medicines to patients in the shortest time possible to radically improve human health in major disease areas.
Tags. Vaccine, Universal influenza, HIV, cancer drug, phase II licensing, opportunity, collaboration.
Tonix Pharma - Late stage clinical development programs in pain and psychiatry
Tonix is a NASDAQ-listed pharmaceutical company with three experimental small molecule prescription medicines in late stage clinical development. This year Tonix will report results from: the Phase 3 fibromyalgia study (Q3); the registration quality Phase 2 study in PTSD (Q2); and the Phase 2 episodic tension-type headache study (Q1).
Tags: Pain, FM, PTSD, Headache
Marlis Dunne, Manager Ireland, Tonix Pharma Limited
Vasgen - Innovative ocular and cancer therapeutics
Vasgen Ltd is an early-stage biotech company based in London UK developing novel monoclonal antibody therapeutics for unmet clinical needs in ophthalmology and cancer medicine. The company is developing a breakthrough antibody platform (AbIMP®) that generates selective inhibitors of therapeutically important but previously intractable metzincin protease targets.
Salman Rahman, CEO, Vasgen